aveo pharmaceuticals news

Zacks Investment Research‘s price objective indicates a potential upside of 7.76% from the company’s current price. AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates - August 11, 2020 - Zacks.com AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in … You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for AVEO was mixed.

We use cookies to understand how you use our site and to improve your experience.

Real time AVEO Pharmaceuticals (AVEO) stock price quote, stock graph, news & analysis. In June the FDA accepted the NDA and set an action date of Mar 31, 2021.

AVEO Pharmaceuticals EPS beats by $0.18, misses on revenue.

Delayed quotes by Sungard.NYSE and AMEX data is at least 20 minutes delayed. AVEO's new drug application submission for tivozanib as a treatment of relapsed or refractory renal cell carcinoma gets acceptance from the FDA.

There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.As an investor, you want to buy stocks with the highest probability of success. Shares rise.This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates 11-08-2020 01:35 via news.yahoo.com AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?AVEO (AVEO) reported earnings 30 days ago.

AVEO Pharmaceuticals saw a drop in short interest in the month of July. The current consensus EPS estimate is -$0.41 on $2.55 million in revenues for the coming quarter and -$1.68 on $7.31 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well.

Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.Real time prices by BATS.

The transaction was disclosed in a filing with the SEC, which is available at Several institutional investors and hedge funds have recently bought and sold shares of AVEO. AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need.

While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock.

The brokerage currently has a $5.00 target price on the biopharmaceutical company’s stock. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.

These returns cover a period from January 1, 1988 through July 6, 2020. 06/23/20 Beneficial Owner of Aveo Pharmaceuticals, Growth Equity buys $7.5M in shares 06/01/20 Aveo Oncology announces FDA acceptance for NDA filing for tivozanib

A quarter ago, it was expected that this cancer drug company would post a loss of $0.50 per share when it actually produced a loss of $0.52, delivering a surprise of -4%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.AVEO, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.75 million for the quarter ended June 2020, missing the Zacks Consensus Estimate by 49.22%. Terms of Use Privacy Policy. As of July 31st, there was short interest totaling 1,390,000 shares, a drop of 24.5% from the July 15th total of 1,840,000 shares.